Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central nervous system with a relapsing and remitting course. We aimed to identify factors associated with the time to next attack, including the effect of the natural disease course and the diverse treatment regimens, by applying a longitudinal statistical analysis to the individual attacks of each patient.In total, 184 acute attacks among 58 patients with either NMO or NMO spectrum disorder with anti-aquaporin-4 antibody were assessed retrospectively. Patient demographics, clinical characteristics at each attack, and type of treatment during inter-attack periods were assessed. The dependent variable was defined as the time from each attack to the next attack (inte...
Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of...
In contrast to MS, in which visual recovery from optic neuritis (ON) is independent of treatment, ON...
Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials Neuromyelitis opt...
Background and Objective: Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of th...
BACKGROUND AND OBJECTIVE: Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of th...
Objective To analyse predictors for relapses and number of attacks under different immunotherapies i...
Objective Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabl...
Background: Neuromyelitis optica spectrum disorder (NMOSD) attacks require an urgent probabilistic a...
Objective Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabl...
Objective: Neuromyelitis optica (NMO) attacks are often severe, difficult to treat, and leave residu...
ObjectiveNeuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and leave resi...
<p>Data shown as median and range (minimum, maximum). EDSS, Kurtzke Expanded Disability Status Scale...
We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optic...
ObjectiveTo explore the outcomes of NMOSD attacks and investigate serum biomarkers for prognosis and...
IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cor...
Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of...
In contrast to MS, in which visual recovery from optic neuritis (ON) is independent of treatment, ON...
Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials Neuromyelitis opt...
Background and Objective: Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of th...
BACKGROUND AND OBJECTIVE: Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of th...
Objective To analyse predictors for relapses and number of attacks under different immunotherapies i...
Objective Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabl...
Background: Neuromyelitis optica spectrum disorder (NMOSD) attacks require an urgent probabilistic a...
Objective Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabl...
Objective: Neuromyelitis optica (NMO) attacks are often severe, difficult to treat, and leave residu...
ObjectiveNeuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and leave resi...
<p>Data shown as median and range (minimum, maximum). EDSS, Kurtzke Expanded Disability Status Scale...
We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optic...
ObjectiveTo explore the outcomes of NMOSD attacks and investigate serum biomarkers for prognosis and...
IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cor...
Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of...
In contrast to MS, in which visual recovery from optic neuritis (ON) is independent of treatment, ON...
Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials Neuromyelitis opt...